Oct 29, 2025 7:00 am EDT Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
Oct 1, 2025 7:00 am EDT Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources
Aug 7, 2025 7:00 am EDT Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates
Jun 18, 2025 7:00 am EDT Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors
May 12, 2025 7:00 am EDT Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates
